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SUCCESS IN THE CONTROL OF THEheart failure epidemic has comefrom advances in understand-ing effective, evidence-based
medical therapies.1 Challenges re-
main, however, in the delivery of these
therapies to patients. Patient nonad-
herence to heart failure drugs ranges
from 30% to 60% and nonadherence to
lifestyle recommendations from50% to
80%, with higher rates occurring in
more socioeconomically disadvan-
taged subgroups.2
To meet the challenge of delivering
evidence-based therapies to patients
with heart failure, research has turned
to the evaluation of disease manage-
ment, remote monitoring, and patient
self-management programs.3-8 Disease
management programs extend medi-
cal care in the outpatient setting but
keep patients in a passive role and, as
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Context Motivating patients with heart failure to adhere to medical advice has not
translated into clinical benefit, but past trials have had methodological limitations.
Objective To determine the value of self-management counseling plus heart failure
education, compared with heart failure education alone, for the primary end point of
death or heart failure hospitalization.
Design, Setting, and Patients The Heart Failure Adherence and Retention Trial
(HART), a single-center, multiple-hospital, partially blinded behavioral efficacy ran-
domized controlled trial involving 902 patients with mild to moderate heart failure and
reduced or preserved systolic function, randomized from the Chicago metropolitan
area between October 2001 and October 2004 and undergoing follow-up for 2 to 3
subsequent years.
Interventions All patients were offered 18 contacts and 18 heart failure educa-
tional tip sheets during the course of 1 year. Patients randomized to the education
group received tip sheets in the mail and telephone calls to check comprehension. Pa-
tients randomized to the self-management group received tip sheets in groups and
were taught self-management skills to implement the advice.
Main Outcome Measure Death or heart failure hospitalization during a median
of 2.56 years of follow-up.
Results Patients were representative of typical clinical populations (mean age,
63.6 years; 47% women, 40% racial/ethnic minority, 52% with annual family
income less than $30 000, and 23% with preserved systolic function). The rate of
the primary end point in the self-management group was no different from that in
the education group (163 [40.1%)] vs 171 [41.2%], respectively; odds ratio, 0.95
[95% confidence interval, 0.72-1.26]). There were no significant differences on any
secondary end points, including death, heart failure hospitalization, all-cause hospi-
talization, or quality of life.
Conclusions Compared with an enhanced educational intervention alone, the ad-
dition of self-management counseling did not reduce death or heart failure hospital-
ization in patients with mild to moderate heart failure.
Trial Registration clinicaltrials.gov Identifier: NCT00018005
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such, raise questions about optimum
duration and cost-effectiveness. Re-
mote monitoring draws on technol-
ogy or telephone contacts to transfer
information on patient status but
raises the same questions about dura-
tion and cost-effectiveness. Patient self-
management programs aim to moti-
vate patients to collaborate in their care
by teaching them self-management
skills. If skills such as self-monitoring
and environmental rearrangement can
be learned, maintained, and used to
implementmedical advice, this is a po-
tentially cost-effective approach to con-
trolling heart failure costs.
Five trials of self-management among
patientswithheart failurehavebeenpub-
lished to date.9-13 All were limited by
small sample sizes (range, 70-197 pa-
tients), short durations (typically 2-3
contacts), and inadequate evaluations of
maintenance of treatment effects (typi-
cally 0-3months).One trial showedben-
efit for a clinical end point (death or
hospitalization),13 but baseline differ-
ences in prognostic factors limit inter-
pretation. Thus, the value of self-
management programs for patientswith
heart failure is questionable.
TheHeart FailureAdherence andRe-
tention Trial (HART) is the largest and
most rigorous trial of self-manage-
ment in heart failure to date. It was de-
signed to assess the value of 1 year of
self-management counseling on death
or heart failure hospitalization in pa-
tients withmild tomoderate heart fail-
ure and reduced or preserved systolic
function.
METHODS
Design
The design andmethods have been re-
ported.14 HART was a single-center,
multiple-hospital, partially blinded be-
havioral efficacy randomized con-
trolled trial.We showed previously that
self-management counseling plus heart
failure education improved self-
efficacy at self-management.15We thus
hypothesized that this benefitwould ex-
tend to improvement in adherence to
drug therapy, sodium restriction, and
depression, which would in turn re-
sult in an improvement in the primary
end point of death or heart failure
hospitalization.
Patientswere randomized in a 1:1 ra-
tio into 2 trial groups and underwent
follow-up for a minimum of 2 years (1
year of treatment and 1 year of follow-
up) and a maximum of 3 years (1 year
of treatment and 2 years of follow-
up), depending on the timing of re-
cruitment. Sample sizewas based on the
assumption that the self-management
intervention would produce a 25% re-
duction in the primary end point, based
on the results of prior self-manage-
ment trials.16,17 The base rate for the pri-
mary endpoint in the control groupwas
assumed to be 15% per year, derived
from rates in the treatment groups of
positive drug trials with similar pa-
tients,18 because these drugs would
likely be the standard of care when
HART ended. Losses and withdrawals
were estimated to be 15%, and sample
size was adjusted by approximately 3%
to allow for interim analyses. Assum-
ing a 2-sided  of .05 and 80% power,
this led to a sample size of 900 pa-
tients, evenly distributed between the
2 treatment groups.
Double-blinding in a behavioral trial
is impossible, because patients are
aware of the treatment they are receiv-
ing. However, HART was a partially
blinded trial. All staff, except for the se-
nior investigators, and all patients were
blinded to trial hypotheses by provid-
ing neutral names for the treatment
groups (ie, “skills training” for the self-
management group and “enhanced edu-
cation” for the education control
group). All investigators and staff, ex-
cept for the data management team,
were blinded to the randomization sta-
tus of the patient. Treatment teams
within each group had no contact with
patients in the other group.
The protocolwas approved by the in-
stitutional committees on human re-
search at the 10 recruiting hospitals. Pa-
tientsprovidedwritten informedconsent.
Trial Patients
Eligible patients had heart failure with
reduced or preserved systolic func-
tion. All patients were receiving some
form of active heart failure treatment,
including diuretics, for the previous 3
months. Heart failurewith reduced sys-
tolic function was defined as ejection
fraction of 40% or less by echocardi-
ography, radiographic ventriculogra-
phy, or radionuclide ventriculogra-
phy. Heart failure with preserved
systolic function was defined as ejec-
tion fraction greater than 40% by 1 of
the 3 methods and 1 or more previous
hospitalizations for heart failure.
Exclusions were factors that would
jeopardize the conduct or rigor of the
trial. These included (1) New York
Heart Association (NYHA) class IV, ow-
ing to low likelihood of benefiting from
behavioral treatment; (2) NYHA class
I, owing to low likelihood of having a
primary end point; (3) heart failure
symptoms that may be eliminated
by surgery (eg, severe aortic stenosis);
(4) uncertain 12-month prognosis
(eg, likelihood of cardiac transplanta-
tion, symptomatic or sustained ven-
tricular tachycardia); (5) severe medi-
cal or psychiatric comorbid condition
(eg, cognitive dysfunction, substance
abuse, psychotic disorder, or active sui-
cidal ideation); (6) patient unwilling-
ness to make lifestyle changes; (7) lo-
gistical barriers (eg, limited mobility,
enrollment in a conflicting protocol,
non–English-speaking); (8) physician
refusal; and (9) patient refusal.
Race/ethnicity was self-reported
using investigator-defined categories
(white/caucasian, black/AfricanAmeri-
can, Hispanic/Latino, Asian American/
Pacific Islander, Native American/
American Indian, or other [specify]).
Recruitment and Randomization
Recruitment of patients was con-
ducted between October 2001 and
October 2004 at 10 recruiting hospi-
tals located throughout the Chicago
metropolitan area. Each recruiting hos-
pital had a cardiologist who served as
the local principal investigator (see list
at end of article). Patients were re-
cruited through inpatient and outpa-
tient screening and through referrals
from cardiologists and internists.
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At the conclusion of the baseline ex-
amination, the nurse coordinator called
the automated randomization service
(Moffitt Cancer Center, University of
South Florida) and treatment assign-
ment was sent to an unblinded staff
member, who mailed a letter of notifi-
cation to the patient. Follow-up by staff
leading the relevant trial group com-
menced approximately 2 to 5 days af-
ter receipt of the letter.
To make group treatment logisti-
cally feasible, randomization was con-
ducted using a stratified block design,
with strata defined as 3 geographic lo-
cations and blocks of size 20. Once 20
patients from the same geographic area
were recruited, randomization re-
sulted in 10 patients assigned to a group
held within their community.
Treatments
Adetaileddescriptionof the1-year treat-
ments tested in HART has been re-
ported.14 The self-managementplus edu-
cation treatment featured group-based
heart failure education plus counseling
tohelppatients developmastery inprob-
lem-solving skills and in 5 self-
management skills. Eighteen 2-hour
groupmeetings of approximately 10 pa-
tients were spread over the course of 1
year. At each meeting, education in the
formof 18Heart FailureTip Sheets from
the American Heart Association (avail-
able at http://www.hearthub.org
/hc-heart-failure.htm) summarized ba-
sic elements of patient management,
including medication adherence, sud-
den weight gain, sodium restriction,
moderate physical activity, and stress
management. Implementationof this ad-
vice was aided by training in 5 self-
management skills: self-monitoring, en-
vironmental restructuring, elicitation of
support from family and friends, cogni-
tive restructuring, and the relaxation re-
sponse. To foster proactivity, a problem-
solving format was used in which
patients identifiedbarriers to implement-
ing the tips and used self-management
skills to overcome them.
Groups were led by health profes-
sionals with advanced degrees, experi-
ence in conducting groups, willingness
to follow a protocol, and demonstrated
competency after a 2-day training ses-
sion. Treatment fidelity was ensured by
(1) audiotaping all sessions, randomly
selecting 5% for review, and providing
needed feedback; (2)monitoringdataon
patients and group leaders to identify
and resolve problems; and (3) conduct-
ing mandatory monthly group leader
meetings.
The education group was conceptu-
alized as an attention control, repre-
sentative of the standard of care in heart
failure education that would be in place
when HART ended. An attention con-
trol, rather than a usual-care control,
minimizes such problems as a placebo
effect inwhich any attention could pro-
mote benefit, the inability to mask pa-
tients to trial hypotheses, and an “un-
derdog” effect that could promote
differential dropout or treatment
crossovers.
Patients randomized to receive edu-
cation received the same 18Heart Fail-
ure Tip Sheets, on the same schedule
as the self-management group meet-
ings but delivered by mail. To ensure
receipt and check comprehension, a
study coordinator contacted the pa-
tient by telephone within 2 to 3 days
of eachmailing. If the tip sheet had not
been read, the call was rescheduled. All
questions about the tip sheets were an-
swered. For concerns unrelated to the
tip sheets, the patient was referred to
his or her primary care clinician.
Study coordinators were trained on
purpose, structure, content, data re-
porting responsibilities, and quality
control procedures. Training in-
cluded role playing to simulate phone
call interactions. Retraining occurred in
response to special problems.
Outcome Measures
The primary end point was assessed in
blinded fashion by a team of cardiolo-
gists (eAppendix, available at http:
//www.jama.com).All patients, or in the
case of death, their family members,
were contacted every 3months by tele-
phone to ascertain occurrence of a death
or hospitalization. Reports of death
were confirmed by medical record,
death certificate, emergency medical
services record, or queries from the So-
cial Security Death Index. Heart fail-
ure admissionswere adjudicated by the
presence of shortness of breath, periph-
eral edema, or chest radiographic evi-
dence of pulmonary edemawithout evi-
dence of another disease process
accounting for symptoms or signs.
Heart failure admissions were con-
firmed if the patient responded to heart
failure therapy or had a documented de-
crease in left ventricular function.
Baseline and annual outcome assess-
ments have been described previ-
ously.14 Briefly, examinations con-
sisted of (1) clinical assessment of
height, weight, respiratory rate, blood
pressure, 6-minute walk, and a blood
draw; (2) medical history including
medical conditions, medications, so-
ciodemographic status, and risk fac-
tors; and (3) questionnaires com-
pleted via interview and self-report. The
patient was asked to place a month’s
supply of an angiotensin-converting en-
zyme (ACE) inhibitor (or -blocker if
the patient was not taking an ACE in-
hibitor) into aMedication EventMoni-
toring System electronic pill cap con-
tainer (MEMS V Trackcap; AARDEX,
Zug, Switzerland) andwas taught to use
it for the ensuingmonth. Adherence to
drug therapy was defined as the per-
centage of pills taken, relative to pills
prescribed, with a cutpoint of 80% or
greater.
Sodium intake was assessed as mil-
ligrams per day based on the CALS
Food FrequencyQuestionnaire, which
was developed to include the main
sources of sodium in the diet.19 Clini-
cally significant sodium intake is 2400
mg/d or less for patients with hyper-
tension20 and 2000 mg/d or less for
those with heart failure.21 A cutpoint of
2400mg/d or less was used because too
fewpatients had an intake of 2000mg/d
or less to make statistical analyses
feasible.
The Self-Efficacy at Self-Manage-
ment Scale, developed specifically for
HART, included 5 items targeting each
of the 5 self-management skills taught
in the intervention. Each itemhad a 10-
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point scale (the higher the score, the
greater the self-efficacy), and the total
score was calculated as the average of
the scores on the 5 items (range, 1-10).
Quality of lifewas assessed as (1) physi-
cal function, using the 10-item sub-
scale from the RAND 36-Item Short-
Form Health Survey (=0.93)22; (2)
vitality, using the 4-item subscale from
the RAND survey (=0.86)22; (3) sat-
isfactionwithhealth and function, using
the 11-item subscale from the Quality
of Life Index–Cardiac (=0.93)23; and
(4) satisfaction with psychological/
spiritual function, using the 11-item
subscale from theQuality of Life Index–
Cardiac (=0.89).23 Psychosocial func-
tion was assessed as (1) major depres-
sive symptoms, using the Geriatric
Depression Scale24 (for which a score
greater than 10 is a sensitive and spe-
cific screen formajor depressive symp-
toms); (2) social support–emotional,
using the 8-item subscale of the Medi-
cal Outcomes Study Social Support
Scale (=0.90)25; and (3) purpose in
life, using the 14-item subscale of the
Psychological Well-Being Scale.26 Co-
morbid conditions were the number of
the following: previous myocardial in-
farction, high blood pressure, diabe-
tes, cancer, stroke, renal disease, ar-
thritis, lung disease, liver disease,
depression, asthma, sleep apnea, and
Parkinson disease. The range (0-13)
was categorized at the median (3).
Family incomewas dichotomized at the
median ($30 000/y). Six-minute walk
was dichotomized at the lowest tertile
(186 m).
Statistical Analyses
Analyseswere conductedusing SAS ver-
sion 9.1 (SAS Institute Inc, Cary, North
Carolina). In accordancewith the analy-
sis plan approved by the data and safety
monitoring board, 2-sided tests and an
overall significance level of P=.05 for
the primary outcome were used. Cat-
egorical variables were compared using
2 tests. Continuous variables were
compared using t tests, except when
skewed distributions warranted use of
the Wilcoxon rank-sum test.
The effect of the 2 treatment groups
on the primary end point and second-
ary clinical end points was compared
using Kaplan-Meier time-to-event
curves and analyzed using the Wil-
coxon test. TheWilcoxon test was used
because the curves clearly indicated that
the hazards were nonproportional. Pa-
tients who were lost to follow-up or
who withdrew consent were included
until the time of censoring. Rates dur-
ing the entire trial period were calcu-
lated as events divided by the number
of patients at risk minus those cen-
sored. Annualized rates were calcu-
lated as events divided by person-
years. 2 Statistics produced P values.
Odds ratios (ORs) were the propor-
tion of at-risk patients with an event in
the self-management group relative to
those in the education group and were
accompanied by 95% confidence inter-
vals (CIs).
The effect of treatment on second-
ary end points was analyzed as a
comparison of change between base-
line and 1 year posttreatment, adjust-
ing for baseline values. The effect of
treatment on behavioral treatment
targets was analyzed using repeated-
measures mixed-effects regression
analyses, with treatment group as the
between-subject factor and time (be-
fore and after the 1-year treatment)
as the repeated within-subject factor.
A significant time effect indicated
that both groups changed, and a sig-
nificant time treatment group inter-
action indicated that one group
changed more than the other.
The effect of treatment in prespeci-
fied subgroups was analyzed by strati-
fying on the relevant subgroup and
comparing treatment group within
strata using ORs and 95% CIs. Be-
cause of the compromised power in this
approach, subgroups were also evalu-
ated by testing for interactions be-
tween subgroup and treatment, adjust-
Figure 1. Study Flow
451 Included in primary analysis 451 Included in primary analysis
3154 Patients screened
902 Randomized
451 Randomized to receive self-management
counseling plus heart failure education
451 Randomized to receive heart failure
education alone
316 Completed follow-up
93 Diedb
22 Withdrewc
20 Lost to follow-up
314 Completed follow-up
102 Diedb
21 Withdrewc
14 Lost to follow-up
383 Received intervention as randomized
68 Did not receive intervention
56 Refused interventiona
12 Died before start of intervention
435 Received intervention as randomized
16 Did not receive intervention
9 Refused interventiona
7 Died before start of intervention
2252 Excluded
511 Patient refusal
465 Did not meet heart failure
inclusion criteria
465 Logistical barriers
307 Uncertain prognosis
193 NYHA class I or IV
38 Physician refusal
37 Heart failure symptoms eliminated
by surgery
12 Unwilling to make lifestyle change
224 Severe medical or psychiatric
comorbidity
NYHA indicates New York Heart Association.
aPatients who refused intervention were continued in follow-up until they completed, died, fully withdrew, or
were lost to follow-up.
b Includes patients who died before start of intervention.
cAll withdrawals were voluntary and patient-initiated.
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ing for covariates, using a parametric
log-logistic accelerated failure timemul-
tivariatemodel,which is appropriate for
use with nonproportional hazard
data.27,28 This model assumes that ex-
planatory variables act multiplica-
tively on the speed with which a pa-
tient proceeds to an event. Acceleration
factors greater than 1 indicate faster
time to event. Amultivariate basemodel
considered all prespecified subgroup
variables (ie, age, sex, education, in-
come, race/ethnicity, functional capac-
ity, comorbid conditions, preserved vs
reduced systolic function, and base-
line drug adherence)14 and other pre-
dictors associatedwith the primary out-
come from the literature (ie, NYHA
class, depression, use of ACE inhibi-
tors or angiotensin receptor blockers,
and use of -blockers) and retained
only those reaching P .15 at each it-
eration using backward elimination. All
prespecified subgroup variables remain-
ing in the base model were tested for
their interactionwith treatment group.
HART featured a cluster design
within the self-management grouponly,
in which patients were treated in 42
groups of approximately 10 patients
each. Because the effect of group
assignment and group leader on the pri-
mary outcome was found to be non-
significant, clustering was not consid-
ered further.
RESULTS
FIGURE 1 presents the trial profile. Of
3154 patients screened during 3 years,
902were enrolled, resulting in a screen-
ing-enrollment ratio of 3.5 patients
screened for every patient enrolled.
The median (interquartile range) fol-
low-up time was 935 (439-1095)
days—918 (464-1095) days in the self-
management group and 963 (389-
1095) days in the education group. Of
the 18 treatment contacts during 1 year,
14 or more (80%) were received by
46.4% of patients in the self-manage-
ment group and 53.1% of those in the
education group.
TABLE 1 presents baseline character-
istics. On average, the cohort was ap-
proximately 64 years of age, 47%
Table 1. Baseline Characteristics in the Total Cohort and by Treatment Group
Characteristic
No. (%)
Overall
(N = 902)
Treatment Group
Self-management
(n = 451)
Education
(n = 451)
Demographic
Age, mean (SD), y 63.6 (13.5) 63.8 (13.7) 63.4 (13.3)
Women 427 (47.3) 209 (46.3) 218 (48.3)
Minority race/ethnicity 362 (40.1) 177 (39.2) 185 (41.0)
High school education 394 (43.7) 197 (43.7) 197 (43.7)
Annual family income$30 000 428 (51.6) 215 (51.9) 213 (51.3)
Unmarried 503 (56.3) 251 (56.3) 252 (56.4)
Medical
Preserved systolic function 208 (23.1) 107 (23.8) 101 (22.4)
NYHA class III 285 (31.6) 144 (31.9) 141 (31.3)
6-min walk, median (IQR), ma 252.9
(149.4-339.0)
264.0
(150.0-349.5)
248.1
(147.0-330.0)
Heart rate, mean (SD)/min 69.7 (14.8) 69.7 (13.9) 69.7 (15.7)
Respiratory rate, mean (SD)/min 15.7 (8.2) 16.0 (7.9) 15.4 (8.5)
Blood pressure, mean (SD), mm Hg
Systolic 120.7 (20.7) 120.5 (20.1) 120.8 (21.3)
Diastolic 70.2 (11.5) 70.2 (11.1) 70.3 (11.9)
Acute physiology score, mean (SD) 2.6 (2.1) 2.6 (2.0) 2.6 (2.1)
History of hypertension 676 (75.2) 345 (76.8) 331 (73.6)
History of diabetes 362 (40.2) 178 (39.6) 184 (40.9)
Comorbid conditions, mean (SD), No. 3.2 (1.7) 3.2 (1.7) 3.3 (1.7)
Medications, mean (SD), No. 6.8 (3.0) 6.8 (3.0) 6.8 (3.0)
Current medication use
ACE inhibitor or angiotensin receptor
blocker
773 (85.7) 383 (84.9) 390 (86.5)
-Blocker 636 (70.5) 320 (71.0) 316 (70.1)
Quality of life, mean (SD)
SF-36
Physical functionb 48.1 (25.0) 48.1 (24.9) 48.1 (25.1)
Vitalityb 46.5 (23.7) 45.9 (23.7) 47.1 (23.6)
Quality of Life Index–Cardiac
Satisfaction with health and functionc 4.3 (1.0) 4.3 (1.1) 4.2 (1.0)
Satisfaction with psychological/
spiritual functionc
4.7 (1.1) 4.7 (1.1) 4.8 (1.0)
Adherence
Nonadherence to drug therapyd 274 (36.5) 143 (38.4) 131 (34.6)
Sodium, median (IQR), mg/de 3338
(2654-4273)
3309
(2695-4253)
3342
(2609-4290)
Current smoker 85 (9.4) 39 (8.6) 46 (10.2)
Body mass index, mean (SD) 31.0 (7.7) 31.1 (7.3) 30.9 (8.0)
Self-efficacy at self-management,
mean (SD)f
7.6 (1.7) 7.6 (1.8) 7.6 (1.6)
Psychosocial
Major depressive symptomsg 265 (29.4) 136 (30.2) 129 (28.7)
Social support–emotional, mean (SD)b,h 75.2 (22.2) 74.3 (22.5) 76.1 (21.9)
Purpose in life, mean (SD)c,i 4.5 (0.8) 4.5 (0.8) 4.5 (0.8)
Abbreviations: ACE, angiotensin-converting enzyme; IQR, interquartile range; NYHA, New York Heart Association; SF-36,
RAND 36-Item Short-Form Health Survey.
aRange, 0-780.
bRange, 0-100; higher scores indicate greater quality of life or emotional support.
cRange, 1-6; higher scores indicate greater satisfaction or life purpose.
dTaking less than 80% of prescribed dose of ACE inhibitor or -blocker.
eRange, 1250-15 678.
fRange, 1-10; higher scores indicate greater self-efficacy.
gMeasured using the Geriatric Depression Scale. A score greater than 10 is sensitive and specific for major depressive
symptoms.
hSubscale of the Medical Outcomes Study Social Support Scale.
iSubscale of the Psychological Well-Being Scale.
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women, 40% self-reported racial/
ethnic minority, and 23% with pre-
served systolic function, making it
representative of typical clinical popu-
lations. Patients were taking an aver-
age of 6.8medications, and 37%did not
adhere to at least 80% of the pre-
scribed dosage of either an ACE inhibi-
tor or -blocker. Median sodium in-
takewas 3338mg/d, wellmore than the
recommended 2000 mg/d for patients
with heart failure21 or 2400 mg/d for
those with hypertension.20 Major de-
pressive symptoms were evident in
29%. There were no statistically sig-
nificant differences between treat-
ment groups for any of the baseline vari-
ables.
FIGURE 2 presents the Kaplan-
Meier estimates of the time to death
or heart failure hospitalization by
treatment group. There was no ben-
efit of self-management compared
with education (Wilcoxon P= .46).
During approximately 2.56 years of
follow-up, there were 163 events
(40.1%) in the self-management
group and 171 (41.2%) in the educa-
tion group (OR, 0.95 [95% CI, 0.72-
1.26]). The annual event rate was
18.4%, based on 883.84 person-years
in the self-management group and
19.2% based on 889.11 person-years
in the education group. eTable 1 pre-
sents ORs and 95%CIs for the second-
ary clinical end points (death: OR, 0.87
[95%CI, 0.63-1.21]; heart failure hos-
pitalization: OR, 1.00 [95% CI, 0.72-
1.38]; all-cause hospitalization: OR,
0.85 [95%CI, 0.62-1.17]). Both groups
had a mean of 0.7 heart failure hospi-
talizations (P=.39). eTable 2 presents
change frombaseline to the 1-year con-
clusion of treatment in secondary end
points. There were no differences be-
tween groups on change inNYHAclass,
6-minute walk, heart rate, respiratory
rate, blood pressure, body mass in-
dex, quality of life, emotional sup-
port, or purpose in life. There were no
adverse or serious adverse events in
either group.
The treatments produced variable
changes on risk factor targets. Self-
efficacy scores improved by 0.2 points
in both groups (P=.008 for time effect).
Major depressive symptoms de-
creased to 90 (20%) in the self-
management group and 99 (22%) in the
education group (P= .008 for time
effect). Restricting sodium to2400mg/d
or less occurred in 126 (28%) patients
in the self-management group and 81
(18%) in the education group (P=.01
for time effect), but there wasmore im-
provement in the self-management
group (P=.02 for treatment time in-
teraction). However, even in the self-
management group, sodium intake re-
mained high, with 325 (72%) having
an intake greater than 2400mg/d. Non-
Figure 2. Time to Death or Heart Failure
Hospitalization by Treatment Group
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There was no benefit of self-management compared
with education (Wilcoxon P=.46). Time indicates time
since randomization.
Table 2. Prespecified Independent Predictors of Death or Heart Failure Hospitalizationa
Predictor Acceleration Factor Parameter Estimates
P
Valuea
Age	65 y 1.57 −0.45 .002
New York Heart Association class III 1.92 −0.65 .001
Major depressive symptoms 1.32 −0.28 .07
	3 Comorbid conditions 1.84 −0.61 .001
Minority race/ethnicity 1.34 −0.29 .057
Income	$30 000 −0.21 .31
Education treatment −.036 .056
Treatment income interaction 0.64 .02
Self-management
Income$30 000 Reference Reference
Income	$30 000 1.23 .31
Education
Income$30 000 1.44 .056
Income	$30 000 0.93 NAb
Abbreviation: NA, not available.
aStatistics reported are derived from log-logistic accelerated failure time models.
bComputationally unobtainable from the accelerated failure time model.
Figure 3. Time to Death or Heart Failure Hospitalization by Treatment Group in Low- and
High-Income Subgroups
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Accelerated failure timemodel that included age, New York Heart Association class, depression, comorbid con-
ditions, race/ethnicity, income, treatment, and the incometreatment interaction resulted in a significant in-
teraction (P=.02). Time indicates time since randomization.
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adherence to the prescribed dosage of
ACE inhibitor or -blocker increased
in both groups by 7 percentage points
(P=.01 for time effect).
The effect of treatment on 9 prespeci-
fied subgroups is presented in the eFig-
ure and eTable 3. There were no sta-
tistically significant differences between
the self-management and education
groups within any subgroup. TABLE 2
presents the results of multivariate ac-
celerated failure time modeling. Ad-
justing for covariates and main ef-
fects, the only significant interaction
between treatment and a subgroupwas
for income (parameter estimate, 0.64;
P=.02). In patients with income less
than $30 000, those randomized to re-
ceive education alone had a statisti-
cally nonsignificant 44% faster time to
event than those randomized to re-
ceive self-management (acceleration
factor, 1.44; P=.056); in patients with
income of $30 000 or greater, therewas
no difference between treatment groups
(FIGURE 3).
COMMENT
Past trials have failed to support the ef-
ficacy of motivating patients to man-
age their heart failure by learning self-
management skills,9-13 but these trials
have been limited byweak designs. The
size, duration, methodological rigor,
and representativeness of HART posi-
tion it well to provide more conclu-
sive results.
We hypothesized that heart failure
education, the standard of care, was
necessary but not sufficient to affect
clinical outcomes. Like any chronic ill-
ness, heart failure should be managed
collaboratively, such that the clinician
prescribes evidence-based therapy and
an informed, proactive patient imple-
ments it.29,30 To enable patients to be
proactive, we reasoned that heart fail-
ure education should be augmented by
training in self-management skills to
help patients implement the educa-
tion. This hypothesis was not sup-
ported. Consistent with past trials, self-
management training plus education
had no benefit compared with educa-
tion alone in reducing death or heart
failure hospitalization in patients with
mild to moderate heart failure.
We believe, however, that the re-
sults of HART provide some direction
for future trials. In post hoc analyses of
prespecified subgroups, we observed a
significant interaction between treat-
ment group and income, suggesting that
self-management counseling may be
beneficial for low-incomepatients.Oth-
ers have suggested that low-income pa-
tientsmayneed special attention to help
them manage chronic illnesses, possi-
bly owing to poor health habits, poor
health literacy, and/or limited health in-
surance.13,31 Were future trials to sup-
port the value of self-management
counseling for low-income patients
with heart failure, this would encour-
age a tailored approach that goes be-
yond the current standard of care.
Technology-assisted remote moni-
toring was not evaluated in this trial.
However, a recent meta-analysis
showed that both telephone monitor-
ing and technology-assisted monitor-
ing achieved a 30% reduction in risk of
heart failure hospitalization com-
paredwith usual care.8 Long-term cost-
effectiveness, however, remains to be
demonstrated.8 It is possible that re-
mote telephone monitoring, such as
that used in theHARTeducation group,
may enhance patient self-monitoring
and thus be an effective way to teach
patient self-management skills. Long-
term cost-effectiveness of such a joint
approach should be studied.
Two limitations of this trial must be
considered. First, the education con-
trol appeared to have been a more ac-
tive treatment than expected. Patients
in the education group received edu-
cation tip sheets by mail, and fol-
low-up telephone calls ensured that
theywere read and comprehended. This
enhanced standard of care improved so-
dium intake, depression, and self-
efficacy at self-management.
Second, the assumption that self-
management counseling would pro-
duce a 25% reduction in the primary
end point compared with education
may have been overly optimistic.
Although the results from early self-
management trials, available when
HART was designed, produced an
effect greater than 25%,16,17 current
heart failure trials seek smaller effects
(eg, HF-ACTION [Heart Failure: A
Controlled Trial Investigating Out-
comes of Exercise Training]: 11%
reduction compared with usual care32;
CHARM [Candesartan in Heart Fail-
ure]: 18% reduction compared with
placebo33). Taking these 2 limitations
together, one possible explanation for
the HART results is that a type II error
attributable to small sample size pre-
cluded the observation of a treatment
benefit.
In summary, the results of HART are
consistent with those of past trials.
There appears to be nobenefit from self-
management counseling on impor-
tant clinical end points in patients
with heart failure. However, given the
epidemic of heart failure burdening
the health care system, identification
of innovative and cost-effective ap-
proaches to outpatient management is
urgently needed. Future trials might
evaluate the benefit of self-manage-
ment counseling in low-income pa-
tients.
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